Patents Assigned to Shionogi & Co., Ltd.
  • Patent number: 11447484
    Abstract: Novel compounds having a D3 receptor antagonistic activity are provided. The compound represented by Formula (I): wherein Ring A is a non-aromatic heterocycle or the like substituted with substituted or unsubstituted aromatic heterocyclyl or the like; R2a to R2d are each independently a hydrogen atom or the like; n is an integer of 0 to 3; Ring B is a non-aromatic carbocycle or the like; R3 is each independently halogen or the like; r is an integer of 0 to 4; -L- is —N(R10)—C(?O), or the like; R10 is a hydrogen atom or the like; R4 is substituted or unsubstituted aromatic heterocyclyl or the like, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 20, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Yusuke Ichihashi, Masanao Inagaki, Koji Masuda
  • Publication number: 20220281890
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: P is hydrogen or a group to form a prodrug; A1 is CR1AR1B, S or O; A2 is CR2AR2B, S or O; A3 is CR3AR3B, S or O; A4 is each independently CR4AR4B, S or O; the number of hetero atoms among atoms constituting the ring which consists of A1, A2, A3, A4, nitrogen atom adjacent to A1 and carbon atom adjacent to A4, is 1 or 2; R1A and R1B are each independently hydrogen, halogen, alkyl, or the like; R2A and R2B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B are each independently hydrogen, halogen, alkyl, or the like; R4A and R4B are each independently hydrogen, halogen, alkyl, or the like; R3A and R3B may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle; R1 is fluorine; m is any integer of 1 to 2; and n is any integer of 1 to 2.
    Type: Application
    Filed: March 8, 2022
    Publication date: September 8, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Makoto KAWAI, Kenji TOMITA, Toshiyuki AKIYAMA, Azusa OKANO, Masayoshi MIYAGAWA
  • Publication number: 20220267778
    Abstract: It was found that nucleic acids for the specific targeting sequences or nucleic acids having the specific sequences have superior suppression activities of MURF1 expression. Pharmaceutical compositions including the nucleic acids as active ingredient are useful for treating or preventing disease accompanied by one or more symptoms selected from the group consisting of decrease in muscle mass, decrease in muscle strength and muscle dysfunction.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Takahiro FUJIWARA, Kazuyoshi TOMITA, Kunitaka NASHIKI, Ayumi NAGASAWA, Ryo YOSHIMOTO, Takahito ITO
  • Publication number: 20220267771
    Abstract: Provided are production methods capable of controlling quality of a bifurcated lipid-linked oligonucleotide, and intermediates which is useful for the production method, has good stability, and is easy to manage and analyze. Specifically, it is a method for producing a bifurcated lipid-linked oligonucleotide including a step of reacting a compound of formula (II): wherein Pro1 to Pro4 are each independently a protecting group; Pro1 and Pro2 or Pro3 and Pro4 may be taken together to form a protecting group; m, n and p are each independently an integer of 0 to 5; and Y is a group of a formula: —P(OC2H4CN)(N(i-Pr)2), or the like, with an oligonucleotide.
    Type: Application
    Filed: June 2, 2020
    Publication date: August 25, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Tetsuya TANINO, Mitsuaki SEKIGUCHI, Shunsuke OCHI, Nobuaki FUKUI
  • Publication number: 20220251107
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Application
    Filed: January 19, 2022
    Publication date: August 11, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Setsuya SHIBAHARA, Nobuaki FUKUI, Toshikatsu MAKI, Kosuke ANAN
  • Publication number: 20220251113
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 21, 2022
    Publication date: August 11, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Hiroyuki TOBINAGA, Koji MASUDA, Masanao INAGAKI, Manami MASUDA
  • Publication number: 20220235047
    Abstract: The present invention relates to novel combinations. The invention also relates to such combinations for use as pharmaceuticals, for instance in the treatment of bacterial diseases, including diseased caused by pathogenic mycobacteria such as non-tuberculosis mycobacteria. In particular, the present invention relates to a medicament, characterized in that a compound having a cytochrome bc1 inhibitory activity, or its pharmaceutically acceptable salt, is combined with clarithromycin or azithromycin, and clofazimine, or their pharmaceutically acceptable salts.
    Type: Application
    Filed: May 28, 2020
    Publication date: July 28, 2022
    Applicants: Shionogi & Co., Ltd., HSIRI THERAPEUTICS, INC.
    Inventors: Kenzo NISHIGUCHI, Satoshi MIYAGAWA, William D. CLAYPOOL, Marvin J. MILLER, Garrett C. MORASKI, Jeffrey S. SCHOREY
  • Patent number: 11389457
    Abstract: The present invention relates to a method for preventing transmission of influenza, wherein said method comprises administering an effective amount of a compound to a patient having an influenza virus infection, herein referred to as “index patient”, wherein the compound has one of the formulae (I) and (II), or its pharmaceutically acceptable salt. The compound to be used in the present invention reduces infectivity of the influenza virus of the index patient, and therefore, reduces the risk of the index patient to trigger an influenza epidemic or an influenza pandemic as compared to a control patient.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: July 19, 2022
    Assignees: Hoffmann-La Roche Inc., Shionogi & Co., Ltd.
    Inventors: Takeshi Noshi, Takahiro Noda, Ryu Yoshida, Takao Shishido, Kaoru Baba, Aeron C. Hurt, Leo Yi Yang Lee, Steffen Wildum, Klaus Kuhlbusch, Barry Clinch, Jan Michal Nebesky, Annabelle Lemenuel, Wendy S. Barclay, Jean-Eric Charoin, Yoshinori Ando
  • Publication number: 20220213121
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Application
    Filed: January 27, 2022
    Publication date: July 7, 2022
    Applicants: Shionogi & Co., Ltd., ViiV Healthcare Company
    Inventors: Brian A. JOHNS, Takashi KAWASUJI, Teruhiko TAISHI, Yoshiyuki TAODA
  • Publication number: 20220178901
    Abstract: When the mesh is placed under the bottom of a blade and over the bottom of a vessel in the dissolution test assembly equipped with either a vessel specified in the dissolution test method of the Japanese Pharmacopoeia, the United States Pharmacopoeia or the European Pharmacopoeia or a vessel used for the dissolution test, and a paddle formed from a blade and a shaft, and the suspensions and the solid dosage forms are added to or placed at the said mesh, a drug dissolves from the said dosage forms and the dissolution ratio variation between the said multiple same dosage forms can be small.
    Type: Application
    Filed: April 7, 2020
    Publication date: June 9, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kensuke HORIUCHI, Satoyo MATSUURA, Maki OKABE
  • Patent number: 11345716
    Abstract: Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X1 is each independently CR4aR4b, X2 is each independently CR4cR4d, Y1 and Y2 are each independently a carbon atom or a nitrogen atom, L is —N(R6)—C(?O)— or the like, W is cyclyl or the like, R2 and R3 are each independently substituted or unsubstituted alkyl or the like, R1a, R1b, R4a to R4d, and R6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: May 31, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Hiroyuki Tobinaga, Koji Masuda, Satoshi Kasuya, Masanao Inagaki, Manami Masuda
  • Publication number: 20220160634
    Abstract: A method for the production of the present disclosure comprises: a) a step of agitating a mixture containing a material to be ground, beads and a dispersion medium in a bead mill; and b) a step of adjusting the pH of the mixture. This method reduces a contamination caused by grinding process using a bead mill.
    Type: Application
    Filed: February 28, 2020
    Publication date: May 26, 2022
    Applicants: Shionogi & Co., Ltd., HIROSHIMA METAL & MACHINERY CO., LTD.
    Inventors: Hironori TANAKA, Yuya OCHII, Tetsuharu IBARAKI
  • Publication number: 20220135577
    Abstract: The present invention provides a compound represented by a following formula. A compound represented by, wherein R1 is hydrogen, hydroxy, or the like; R2a and R2b may be taken together with an adjacent carbon atom to form ring B, ring B is a substituted or unsubstituted non-aromatic carbocycle or a substituted or unsubstituted non-aromatic heterocycle; R3a is hydrogen, halogen, hydroxy, or the like; R3b is hydrogen, halogen, hydroxy, or the like; R4a is a group represented by formula: L3 is a single bond or substituted or unsubstituted alkylene, R7 is hydrogen, halogen, hydroxy, or the like, and R4b is halogen, cyano, carboxy, or the like, or its pharmaceutically acceptable salt.
    Type: Application
    Filed: January 10, 2020
    Publication date: May 5, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Yusuke TATENO, Manabu KATOU, Toshihiro WADA
  • Patent number: 11304937
    Abstract: The present invention provides a particle comprising pirfenidone and a lipid, particularly magnesium stearate, and having a mean particle diameter of 5 ?m or less, and a powder formulation comprising the particle and a carrier.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: April 19, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Takeshi Funaki, Yukiko Nishino, Yuki Masuda, Koichi Tsubone
  • Patent number: 11306106
    Abstract: The present invention provides a pharmaceutical composition containing the following compound having antiviral action: wherein each of the symbols is defined in the specification.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: April 19, 2022
    Assignee: Shionogi & Co., Ltd.
    Inventor: Makoto Kawai
  • Patent number: 11286262
    Abstract: The present invention provides industrially suitable processes for preparing intermediates in the production of substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity. In the process as shown below, wherein each symbol is as defined in the specification, an optically active substituted tricyclic pyridone derivative of the formula (VII) is obtained in high yield and high enantioselectivity by subjecting a compound of the formula (III) or (VI) to intramolecular cyclization with controlling stereochemistry to obtain a compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group thereof.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 29, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Kazuya Okamoto, Tatsuhiko Ueno
  • Publication number: 20220073518
    Abstract: The present invention provides the compound represented by the following formula (I): wherein a moiety represented by formula: or the like. The symbols are defined in the specification. The compounds of the present invention have MGAT2 inhibitory activity, and are useful as a medicine for treatment of MGAT2-associated diseases including obesity, metabolic syndrome, hyperlipidemia, hypertriglyceridemia, hyper-VLDL-triglyceridemia, hyperfattyacidemia, diabetes mellitus, and arteriosclerosis.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 10, 2022
    Applicant: Shionogi & Co., Ltd.
    Inventors: Kouhei NODU, Yusuke TATENO, Kengo MASUDA, Yuji NISHIURA, Yoshikazu SASAKI, Yu HINATA
  • Patent number: 11267823
    Abstract: Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1?,2?:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: March 8, 2022
    Assignees: SHIONOGI & CO., LTD., VIIV HEALTHCARE COMPANY
    Inventors: Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
  • Publication number: 20220064312
    Abstract: Disclosed is a novel anti-CCR8 antibody. The antibody can be used for treating or preventing cancers or the like.
    Type: Application
    Filed: December 27, 2019
    Publication date: March 3, 2022
    Applicants: Shionogi & Co., Ltd., Osaka University
    Inventors: Mai Yoshikawa, Tatsuya Takahashi, Junji Onoda, Sunao Imai, Etsuo Nakamura, Kentaro Furukawa, Tsuguo Miyauchi, Tetsuya Yoshida, Morio Nagira, Naganari Ohkura, Atsushi Tanaka, Shimon Sakaguchi, Hisashi Wada, Atsunari Kawashima
  • Patent number: 11261198
    Abstract: The present invention provides a process for preparing a compound of the formula (II): wherein R2 is unsubstituted alkyl, characterized by reacting a compound of the formula (I): wherein R1 is hydrogen or a protecting group other than unsubstituted alkyl, with a compound of the formula: R2—OH, wherein R2 is as defined above, in the presence of a sodium salt and/or a magnesium salt.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: March 1, 2022
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Setsuya Shibahara, Kosuke Anan